Journal of the National Cancer Institute
-
J. Natl. Cancer Inst. · Oct 2011
Randomized Controlled Trial Comparative StudyProof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine.
Three-dose regimens for human papillomavirus (HPV) vaccines are expensive and difficult to complete, especially in settings where the need for cervical cancer prevention is greatest. ⋯ Four years after vaccination of women who appeared to be uninfected, this nonrandomized analysis suggests that two doses of the HPV16/18 vaccine, and maybe even one dose, are as protective as three doses.